# A Study Investigating Intravenous Human Normal Immune Globulin (IGIV) 10% in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

> **NCT06752356** · PHASE3 · RECRUITING · sponsor: **Kedrion S.p.A.** · enrollment: 161 (estimated)

## Conditions studied

- Chronic Inflammatory Demyelinating Polyneuropathy

## Interventions

- **BIOLOGICAL:** Immune globulin (human) 10% solution for intravenous administration

## Key facts

- **NCT ID:** NCT06752356
- **Lead sponsor:** Kedrion S.p.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-04
- **Primary completion:** 2027-12-20
- **Final completion:** 2027-12-27
- **Target enrollment:** 161 (ESTIMATED)
- **Last updated:** 2026-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06752356

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06752356, "A Study Investigating Intravenous Human Normal Immune Globulin (IGIV) 10% in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06752356. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*